In contrast to antiretroviral drugs, humanized monoclonal antibodies mainly targeted for the selective removal of HTLV-1-infected and activated CD4+ T cells have been used and demonstrated some improvements in HAM/TSP patients. This evidence concerns the gene CD4 and tropical spastic paraparesis.